drugset / Trial / NCT00180895
Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL
Phase 2
Terminated
40 enrolled
Gustave Roussy, Cancer Campus, Grand Paris
Hoffmann-La Roche · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multicentric phase II study of Mabthera (rituximab) in children and adolescents with relapsed and refractory B-cell NHL/L3ALL. The primary objective is to determine the response rate of Rituximab as single agent in relapsed or refractory Burkitt lymphoma, L3 acute leukemia, large B-cell lymphoma and non subclassified aggressive B-cell NHL
Timeline
- Start
- 2004-06
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |